Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients.

[1]  Hiroshi Nishimoto,et al.  Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. , 2012, Japanese journal of clinical oncology.

[2]  J. Tokar,et al.  Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  Y. Tachimori,et al.  Comprehensive Registry of Esophageal Cancer in Japan, 2004 , 2012, Esophagus.

[4]  K. Muro,et al.  Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). , 2011, International journal of radiation oncology, biology, physics.

[5]  K. Shirai,et al.  Dose-volume histogram parameters and clinical factors associated with pleural effusion after chemoradiotherapy in esophageal cancer patients. , 2011, International journal of radiation oncology, biology, physics.

[6]  Hisao Ito,et al.  Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. , 2009, International journal of radiation oncology, biology, physics.

[7]  R. Mohan,et al.  Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. , 2008, International journal of radiation oncology, biology, physics.

[8]  A. Akobeng,et al.  Understanding diagnostic tests 3: receiver operating characteristic curves , 2007, Acta paediatrica.

[9]  K. Kaneko,et al.  Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma , 2006, Journal of Gastroenterology.

[10]  D. Tait,et al.  Quantification and reduction of cardiac dose in radical radiotherapy for oesophageal cancer. , 2005, The British journal of radiology.

[11]  V. Gebski,et al.  Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. , 2005, The Lancet. Oncology.

[12]  S. Yoshida,et al.  Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. , 2003, International journal of radiation oncology, biology, physics.

[13]  Narikazu Boku,et al.  Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Yoshida,et al.  Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Cooper,et al.  Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. , 1999, JAMA.

[16]  A. Dixon,et al.  CT dimensions of the normal pericardium. , 1998, The British journal of radiology.

[17]  R K Ten Haken,et al.  Fraction size and dose parameters related to the incidence of pericardial effusions. , 1998, International journal of radiation oncology, biology, physics.